Tilray | TRLY - Interest Expense On Debt

Stock Price
9.23
Daily Change
0.08 0.87%
Monthly
-8.43%
Yearly
960.92%
Q2 Forecast
8.92

Tilray reported $6.7M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 4.83M 359.32M Dec/2025
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Aurora Cannabis CAD 2.11M 116K Dec/2025
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 7.34M 1.46M Dec/2025
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 60M 30M Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
IQVIA Holdings USD 193M 4M Dec/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 128M 3M Sep/2025
Revvity USD 23.51M 742K Dec/2025
Tectonic Therapeutic USD 12K 276.99M Dec/2025
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 119.6M 0 Dec/2025
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025
Zealand Pharma A/S 7.07M 74K Dec/2025